Drug Profile

Ketamine/Prucalopride - Columbia University

Alternative Names: SPC-14

Latest Information Update: 07 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Columbia University
Class Antidementias
Mechanism of Action NMDA receptor antagonists; Serotonin 4 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Alzheimer's disease

Most Recent Events

28 Apr 2025 Silo Pharma has patents pending for Ketamine/Prucalopride in USA
28 Apr 2025 Pharmacodynamics data from a preclinical studies for Alzheimer's disease released by Silo Pharma
16 Jul 2024 Silo Pharma in-licenses SPC 14 from Columbia University

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com